Cargando…

Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study

BACKGROUND: Many novel drug delivery systems have been extensively studied to exploit the full therapeutic potential of SN38, which is one of the most potent antitumor analogs of camptothecins (CPTs), whose clinical application is seriously hindered by poor water solubility, low plasmatic stability,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Chan, Zhang, Yang, Yang, Daoqiu, Zhang, Jinfeng, Ma, Juanjuan, Cheng, Dan, Chen, Jianming, Deng, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304248/ https://www.ncbi.nlm.nih.gov/pubmed/30587986 http://dx.doi.org/10.2147/IJN.S187906

Ejemplares similares

Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy
por: Xing, Jing, et al.
Publicado: (2019)

Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy
por: Bi, Ye, et al.
Publicado: (2018)

Investigation into the Efficacy of Val-SN-38, a Valine-Ester Prodrug of the Anti-Cancer Agent SN-38
por: Kwak, Eun-Young, et al.
Publicado: (2012)

Augmented Anticancer Effects of Cantharidin with Liposomal Encapsulation: In Vitro and In Vivo Evaluation
por: Zhang, Xue, et al.
Publicado: (2017)

Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy
por: Gu, Yongwei, et al.
Publicado: (2019)

An esterase-activatable prodrug formulated liposome strategy: potentiating the anticancer therapeutic efficacy and drug safety
por: Shi, Linlin, et al.
Publicado: (2021)

In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes
por: Chen, Min, et al.
Publicado: (2017)

SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study
por: Fang, Yi-Ping, et al.
Publicado: (2018)

Synthesis and Biological Evaluation of Novel 10-Substituted-7-ethyl-10-hydroxycamptothecin (SN-38) Prodrugs
por: Zhou, Mo, et al.
Publicado: (2014)

Carbon dots conjugated to SN38 for improved colorectal anticancer therapy
por: Mattinzoli, Deborah, et al.
Publicado: (2022)

Characterization of 9-Nitrocamptothecin Liposomes: Anticancer Properties and Mechanisms on Hepatocellular Carcinoma In Vitro and In Vivo
por: Zheng, Shunzhen, et al.
Publicado: (2011)

Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity
por: Liu, Yi, et al.
Publicado: (2015)

Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
por: Santi, Daniel V., et al.
Publicado: (2021)

Effective Irinotecan (CPT‐11)‐containing Liposomes: Intraliposomal Conversion to the Active Metabolite SN‐38
por: Sadzuka, Yasuyuki, et al.
Publicado: (1999)

Preparation and evaluation of a Rubropunctatin-loaded liposome anticancer drug carrier
por: Xu, Dongling, et al.
Publicado: (2020)

The anticancer efficacy of paclitaxel liposomes modified with low-toxicity hydrophobic cell-penetrating peptides in breast cancer: an in vitro and in vivo evaluation
por: Zhang, Qi, et al.
Publicado: (2018)

Co-Prodrugs of 7-Ethyl-10-hydroxycamptothecin and Vorinostat with in Vitro Hydrolysis and Anticancer Effects
por: Liu, Shuangxi, et al.
Publicado: (2019)

PEGylation of lipophilic SN38 prodrug with DSPE-mPEG(2000) versus cremophor EL: comparative study for intravenous chemotherapy
por: Zeng, Jun, et al.
Publicado: (2019)

Synthesis, characterization, and evaluation of mPEG–SN38 and mPEG–PLA–SN38 micelles for cancer therapy
por: Xie, Jing, et al.
Publicado: (2016)

An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo
por: Mayr, Josef, et al.
Publicado: (2017)

Development of artesunate intelligent prodrug liposomes based on mitochondrial targeting strategy
por: Gu, Liwei, et al.
Publicado: (2022)

Disulfide Bond-Based SN38 Prodrug Nanoassemblies with High Drug Loading and Reduction-Triggered Drug Release for Pancreatic Cancer Therapy
por: Zhong, Zhi-Xin, et al.
Publicado: (2023)

Structure-based design of anticancer prodrug PABA/NO
por: Ji, Xinhua, et al.
Publicado: (2009)

Mild Hyperthermia Responsive Liposomes for Enhanced In Vitro and In Vivo Anticancer Efficacy of Doxorubicin against Hepatocellular Carcinoma
por: Rahim, Muhammad Abdur, et al.
Publicado: (2021)

Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells
por: TANAKA, TETSUJI, et al.
Publicado: (2012)

Amino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in Rats
por: Vacondio, Federica, et al.
Publicado: (2015)

A Photocleavable Amphiphilic Prodrug Self-Assembled Nanoparticles with Effective Anticancer Activity In Vitro
por: Chen, Ji, et al.
Publicado: (2019)

Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation
por: Yang, Wenqian, et al.
Publicado: (2019)

Synthesis of Two Methotrexate Prodrugs for Optimizing Drug Loading into Liposomes
por: Di Francesco, Valentina, et al.
Publicado: (2021)

A novel microfluidic liposomal formulation for the delivery of the SN-38 camptothecin: characterization and in vitro assessment of its cytotoxic effect on two tumor cell lines
por: Casadó, Ana, et al.
Publicado: (2018)

Disulfide Bond Bridge Insertion Turns Hydrophobic Anticancer Prodrugs into Self-Assembled Nanomedicines
por: Wang, Yongjun, et al.
Publicado: (2014)

Magnetic-Fe/Fe(3)O(4)-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages
por: Wang, Hongwang, et al.
Publicado: (2012)

The Potential of Liposomes with Carbonic Anhydrase IX to Deliver Anticancer Ingredients to Cancer Cells in Vivo
por: Ng, Huei Leng Helena, et al.
Publicado: (2014)

An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells
por: Yashiro, M, et al.
Publicado: (2011)

Stealth Liposomes (PEGylated) Containing an Anticancer Drug Camptothecin: In Vitro Characterization and In Vivo Pharmacokinetic and Tissue Distribution Study
por: Sivadasan, Durgaramani, et al.
Publicado: (2022)

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
por: Huang, Jingjing, et al.
Publicado: (2022)

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents
por: Omran, Ziad, et al.
Publicado: (2021)

Improving cellular uptake and bioavailability of periplocymarin-linoleic acid prodrug by combining PEGylated liposome
por: Zhang, Huiyun, et al.
Publicado: (2022)

Evaluation of the in vivo genotoxicity of liposomal formulation for delivering anticancer estrogenic derivative (ESC8) in a mouse model
por: Ahmad, Ajaz, et al.
Publicado: (2019)

Remote loading paclitaxel–doxorubicin prodrug into liposomes for cancer combination therapy
por: Yu, Jiang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pba5foca4dmgbi1439eub2sq7g